Published in J Biol Chem on February 10, 1995
Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation, and PHAS-I phosphorylation by insulin requires insulin receptor substrate 1 and phosphatidylinositol 3-kinase. Mol Cell Biol (1996) 1.70
Role of insulin-induced reactive oxygen species in the insulin signaling pathway. Antioxid Redox Signal (2005) 1.60
Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J Clin Invest (1997) 1.58
Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP. Mol Cell Biol (2005) 1.41
Increased abundance of the receptor-type protein-tyrosine phosphatase LAR accounts for the elevated insulin receptor dephosphorylating activity in adipose tissue of obese human subjects. J Clin Invest (1995) 1.11
Leukocyte antigen-related protein tyrosine phosphatase negatively regulates hydrogen peroxide-induced vascular smooth muscle cell apoptosis. J Biol Chem (2008) 0.90
Receptor protein tyrosine phosphatase-receptor tyrosine kinase substrate screen identifies EphA2 as a target for LAR in cell migration. Mol Cell Biol (2013) 0.86
T cell protein tyrosine phosphatase (TCPTP) deficiency in muscle does not alter insulin signalling and glucose homeostasis in mice. Diabetologia (2011) 0.82
A novel liver specific isoform of the rat LAR transcript is expressed as a truncated isoform encoded from a 5'UTR located within intron 11. BMC Mol Biol (2009) 0.80
The linkage between beta1 integrin and the actin cytoskeleton is differentially regulated by tyrosine and serine/threonine phosphorylation of beta1 integrin in normal and cancerous human breast cells. BMC Cell Biol (2001) 0.79
Variants of insulin-signaling inhibitor genes in type 2 diabetes and related metabolic abnormalities. Int J Genomics (2013) 0.77
Identification of novel, less toxic PTP-LAR inhibitors using in silico strategies: pharmacophore modeling, SADMET-based virtual screening and docking. J Mol Model (2011) 0.76
Identification of receptor protein tyrosine phosphatases (RPTPs) as regulators of receptor tyrosine kinases (RTKs) using an RPTP siRNA-RTK substrate screen. Methods Mol Biol (2015) 0.75
Establishment of Leptin-Responsive Cell Lines from Adult Mouse Hypothalamus. PLoS One (2016) 0.75
Correlation of alpha-fetoprotein expression in normal hepatocytes during development with tyrosine phosphorylation and insulin receptor expression. Mol Biol Cell (1998) 0.75
In utero exposure to diesel exhaust particulates is associated with an altered cardiac transcriptional response to transverse aortic constriction and altered DNA methylation. FASEB J (2017) 0.75
Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature (1991) 6.50
Regenerative proliferation in inner ear sensory epithelia from adult guinea pigs and humans. Science (1993) 2.83
Insulin-stimulated hydrogen peroxide reversibly inhibits protein-tyrosine phosphatase 1b in vivo and enhances the early insulin action cascade. J Biol Chem (2001) 2.60
Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. J Clin Invest (1977) 2.46
Reducing unnecessary coronary care unit admissions: a comparison of three decision aids. J Gen Intern Med (1991) 2.16
Hydrogen peroxide generated during cellular insulin stimulation is integral to activation of the distal insulin signaling cascade in 3T3-L1 adipocytes. J Biol Chem (2001) 2.06
Uptake of branched-chain alpha-keto acids in Bacillus subtilis. J Bacteriol (1976) 1.87
Regulation of the insulin signalling pathway by cellular protein-tyrosine phosphatases. Mol Cell Biochem (1998) 1.73
Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem (2001) 1.67
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab (2010) 1.67
Adult olfactory epithelium contains multipotent progenitors that give rise to neurons and non-neural cells. J Comp Neurol (1998) 1.67
Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J Clin Invest (1997) 1.58
Pharmacologic considerations in the treatment of anxiety and depression in medical practice. Med Clin North Am (1971) 1.54
Homozygous nonsense mutation in the insulin receptor gene of a patient with severe congenital insulin resistance: leprechaunism and the role of the insulin-like growth factor receptor. Clin Endocrinol (Oxf) (1996) 1.42
Somatomedin-C receptors and growth effects in human breast cells maintained in long-term tissue culture. Cancer Res (1984) 1.40
Interleukin-1 is cytoprotective, antisecretory, stimulates PGE2 synthesis by the stomach, and retards gastric emptying. Life Sci (1991) 1.39
Osmotic loading of neutralizing antibodies demonstrates a role for protein-tyrosine phosphatase 1B in negative regulation of the insulin action pathway. J Biol Chem (1995) 1.29
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab (2011) 1.28
Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte development. Proc Natl Acad Sci U S A (1986) 1.27
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract (2010) 1.24
Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract (2008) 1.24
A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. J Clin Psychiatry (1985) 1.20
Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor. J Biol Chem (1998) 1.19
Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab (2009) 1.18
The type II insulin-like growth factor receptor does not mediate deoxyribonucleic acid synthesis in human fibroblasts. J Clin Endocrinol Metab (1987) 1.17
Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226. J Immunol (1993) 1.17
Increased abundance of specific skeletal muscle protein-tyrosine phosphatases in a genetic model of insulin-resistant obesity and diabetes mellitus. Metabolism (1995) 1.16
Improved sensitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue. Metabolism (1997) 1.16
Caloric restriction and 7,12-dimethylbenz(a)anthracene-induced mammary tumor growth in rats: alterations in circulating insulin, insulin-like growth factors I and II, and epidermal growth factor. Cancer Res (1989) 1.15
Selective serotonin reuptake inhibitors in affective disorders--I. Basic pharmacology. J Psychopharmacol (1998) 1.15
Incidence and distribution of experimental metastases in mutant mice with defective organ microenvironments (genotypes Sl/Sld and W/Wv). Cancer Res (1992) 1.14
The somatomedin C binding protein: evidence for a heterologous subunit structure. J Clin Endocrinol Metab (1980) 1.13
Primary objective of study of sitagliptin in patients with ESRD on dialysis. Am J Kidney Dis (2013) 1.11
Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors. Int J Cancer (1987) 1.11
Increased abundance of the receptor-type protein-tyrosine phosphatase LAR accounts for the elevated insulin receptor dephosphorylating activity in adipose tissue of obese human subjects. J Clin Invest (1995) 1.11
Modulating an oxidative-inflammatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function. Int J Clin Pract (2008) 1.10
The insulin receptor and its substrate: molecular determinants of early events in insulin action. Recent Prog Horm Res (1993) 1.09
Insulin-like growth factor-I binds selectively to human peripheral blood monocytes and B-lymphocytes. J Clin Endocrinol Metab (1991) 1.07
Insulin receptor protein-tyrosine phosphatases. Leukocyte common antigen-related phosphatase rapidly deactivates the insulin receptor kinase by preferential dephosphorylation of the receptor regulatory domain. J Biol Chem (1992) 1.06
Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin (2005) 1.04
Suppressor of cytokine signaling (SOCS)-3 protein interacts with the insulin-like growth factor-I receptor. Biochem Biophys Res Commun (2000) 1.03
Dexamethasone, OB gene, and leptin in humans; effect of exogenous hyperinsulinemia. J Clin Endocrinol Metab (1997) 1.03
A longitudinal study of the relationship of plasma somatomedin-C concentration to the pubertal growth spurt. Am J Dis Child (1987) 1.03
Immunoreactive Akt, PI3-K and ERK protein kinase expression in ischemic rat brain. Neurosci Lett (1999) 1.03
Formation and turnover of triglyceride-rich vesicles in the chick liver cell. Effects of cAMP and carnitine on triglyceride mobilization and conversion to ketones. J Biol Chem (1981) 1.00
High affinity antibody from hen's eggs directed against the human insulin receptor and the human IGF-I receptor. Anal Biochem (1988) 1.00
The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab (2011) 0.99
Estrogen and progesterone receptor detection in archival formalin-fixed, paraffin-embedded tissue from breast carcinoma: a comparison of immunohistochemistry with the dextran-coated charcoal assay. Mod Pathol (1992) 0.98
The transmembrane protein-tyrosine phosphatase LAR modulates signaling by multiple receptor tyrosine kinases. J Biol Chem (1996) 0.98
Enhanced phosphorylation of PTEN in rat brain after transient middle cerebral artery occlusion. Brain Res (2002) 0.98
Direct localization of a beta-subunit domain on the three-dimensional structure of Escherichia coli RNA polymerase. Proc Natl Acad Sci U S A (2000) 0.98
Evidence for the direct interaction of the insulin-like growth factor I receptor with IRS-1, Shc, and Grb10. Mol Endocrinol (1996) 0.97
POEMS syndrome with myocardial infarction: observations concerning pathogenesis and review of the literature. Semin Arthritis Rheum (1992) 0.96
Ovine placental lactogen induces somatomedin: a a possible role in fetal growth. Endocrinology (1977) 0.96
Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose homeostasis. Diabetes (1998) 0.95
Alterations in specific protein-tyrosine phosphatases accompany insulin resistance of streptozotocin diabetes. Am J Physiol (1995) 0.95
Pitfalls in the somatomedin-C radioimmunoassay. J Clin Endocrinol Metab (1982) 0.95
Use of an anaerobic environment to preserve the endogenous activity of protein-tyrosine phosphatases isolated from intact cells. FASEB J (2001) 0.95
Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy. J Clin Endocrinol Metab (1990) 0.94
Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes Obes Metab (2006) 0.93
c-Jun N-terminal kinase (JNK) and JNK interacting protein response in rat brain after transient middle cerebral artery occlusion. Neurosci Lett (2000) 0.93
Use of digitonin-permeabilized adipocytes for cAMP studies. Methods Enzymol (1988) 0.92
Molecular defects in insulin action. Science (1989) 0.92
Effect of tumor necrosis factor-alpha on the phosphorylation of tyrosine kinase receptors is associated with dynamic alterations in specific protein-tyrosine phosphatases. J Cell Biochem (1997) 0.91
Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes. Diabetes Obes Metab (2011) 0.91
A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents. Diabetes Obes Metab (2011) 0.91
Giant splenomegaly in sarcoidosis. Br J Surg (1968) 0.91
Molecular cloning and expression of a unique receptor-like protein-tyrosine-phosphatase in the leucocyte-common-antigen-related phosphate family. Biochem J (1994) 0.90
Activation of phosphatidylinositol-3-kinase by platelet-derived growth factor and insulin-like growth factor-1 is inhibited by a transmembrane phosphotyrosine phosphatase. J Biol Chem (1993) 0.90
Phosphorylation of retinoblastoma protein in rat brain after transient middle cerebral artery occlusion. Neuropathol Appl Neurobiol (2000) 0.89
Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab (2011) 0.89
Functional insulin and insulin-like growth factor-1 receptors are preferentially expressed in multiple myeloma cell lines as compared to B-lymphoblastoid cell lines. Cancer Res (1994) 0.88
An evaluation of the importance of lysosomal and neutral cytosol proteases in insulin degradation by adipocytes. Endocrinology (1981) 0.88
Depot-specific variation in protein-tyrosine phosphatase activities in human omental and subcutaneous adipose tissue: a potential contribution to differential insulin sensitivity. J Clin Endocrinol Metab (2001) 0.88
Novel approach to the study of the regulation of hormone-sensitive lipase in rat adipocytes. Permeabilization of cells with digitonin. Eur J Biochem (1983) 0.88
Suppression of insulin receptor activation by overexpression of the protein-tyrosine phosphatase LAR in hepatoma cells. Cell Signal (1996) 0.87
Tricarboxylic acid cycle intermediates and the control of fatty acid synthesis and ketogenesis. Curr Top Cell Regul (1981) 0.87
Identification of persistent defects in insulin receptor structure and function capillary endothelial cells from diabetic rats. J Clin Invest (1989) 0.87
Insulin degradation by insulin target cells. Metabolism (1981) 0.87
Growth hormone release in response to human pancreatic tumor growth hormone-releasing hormone-40 in children with short stature. J Clin Endocrinol Metab (1984) 0.87
Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. Metabolism (2000) 0.87
Dissociation of PTPase levels from their modulation of insulin receptor signal transduction. Cell Signal (1999) 0.87
The PI3-kinase serine kinase phosphorylates its p85 subunit and IRS-1 in PI3-kinase/IRS-1 complexes. Biochem Biophys Res Commun (1995) 0.86
PTP LAR expression compared to prognostic indices in metastatic and non-metastatic breast cancer. Breast Cancer Res Treat (2000) 0.86
Control of ketogenesis and fatty-acid synthesis at the mitochondrial branch-point for acetyl-CoA in the chick liver cell: effect of adenosine 3',5'-monophosphate. Eur J Biochem (1982) 0.86
Insulin-mediated antilipolysis in permeabilized rat adipocytes. J Biol Chem (1984) 0.86
Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol (2000) 0.86
Modulation of insulin signal transduction by eutopic overexpression of the receptor-type protein-tyrosine phosphatase LAR. Mol Endocrinol (1996) 0.86
Insulin receptor and epidermal growth factor receptor dephosphorylation by three major rat liver protein-tyrosine phosphatases expressed in a recombinant bacterial system. Biochem J (1992) 0.86
Functional association between the insulin receptor and the transmembrane protein-tyrosine phosphatase LAR in intact cells. J Biol Chem (1997) 0.85
Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes. Int J Clin Pract (2011) 0.85
EGF-dependent cell cycle progression is controlled by density-dependent regulation of Akt activation. Exp Cell Res (2004) 0.85
Insulin degradation by adipose tissue. Studies at several levels of cellular organization. Biochem J (1980) 0.85